Q2 2022 Zoetis Inc Earnings Call
Of Russia, and Ukraine in the first half our international sales would have grown 9% operationally.
This is the latest example of how our diverse portfolio and global footprint drive steady and sustainable growth for the business, while some markets may be experiencing setbacks in the quarter other markets like the U S Australia, Southern Europe and other emerging markets are driving our performance.
In the second half, we see China, returning to stronger growth if COVID-19 stays in check and we continue to expect the diversity across geographies and species to remain strong.
In terms of livestock, we expect continued pressure from generic competition, primarily in U S cattle and poultry products. However, we are generating growth across various livestock species in markets outside the U S and fish continues to perform exceptionally well.
Finally, like many companies we are managing through supply constraints. This year with certain products. We continue working hard to optimize our supply chain. This year. So we can meet the increasing demand for certain key products.
Looking ahead, we will continue to invest in the resources DTC marketing and manufacturing capacity, we need to support our future growth and achieve results for our customers and shareholders.
We are advancing our driven to care sustainability goals that we established last year and we published our 2021 progress update and ESG metrics in the second quarter, highlighting achievements towards our D. Eni aspirations expanded clinical and support for the veterinary profession.
We are committed to staying on our journey to be the most sustainable animal health company in the world.
We also continued to invest in R&D business development, and new capabilities across the business to enhance our portfolio and ensure our long term growth.
In the second quarter, we continued to receive approvals for new products like pullback for Serta H V. P. IV DNV expand key franchises like Apple <unk> into new markets and acquire new businesses to complement our portfolio such as base pause at pet care Genetics company.
In closing our business continues to perform extraordinarily well and one of the most dynamic markets I've ever seen.
Diversity innovation and customer focus are cornerstones for excellence I want to thank our colleagues for their tenacity commitment and resilience as we continue to deliver for our customers and shareholders.
Now, let me hand things off to Whitney.
Thank you Kristen and good morning, everyone.
As Chris mentioned, we had a very strong quarter with growth across a number of our core franchises and the continued resilience of our end markets.
Today I'll focus my comments on our second quarter financial performance. The key drivers contributing to our performance and provide an update on our full year of 2023 guidance.
In the second quarter regenerative revenue of $2 1 billion.
5% on a reported basis and 8% on operational basis.
Adjusted net income of $567 million was flat on a reported basis and grew 9% on an operational basis.
Of the 8% operational revenue growth, 3% is from price and 5% from volume.
Volume growth consisted of 6% from new products, which include suburb of trio and the gorilla, 2% from key dermatology products, while other in line products declined 3%.
The decline in the other analog products was expected and largely the result of the impact of intermittent supply challenges and generic competition for Jackson.
Companion animal products continued to be the primary driver of growth growing 14% operationally with lifestyle declining 1% on an operational basis in the quarter.
<unk> was the largest contributor to growth in the quarter.
<unk> posted global revenue of $237 million, representing operational growth of 72% versus the comparable 2021 period.
We also continue to experience better than expected results from our <unk> franchise outside the U S.
Where we had sales of almost $30 million.
We expect to continue to grow the addressable market for flea tick and heartworm globally, and see significant headroom for growth with brands like <unk> and trio.
Meanwhile, our key dermatology products Epiphone, sorry to point had significant global growth again with $315 million of revenue, representing 16% operational growth against a robust prior year in which these products with 22% operationally in the second quarter of 2021.
In Europe , our monoclonal antibodies phosphorus worse pain in dogs and cats also meaningfully contributed to growth posting $31 million in sales.
Our global companion animal diagnostics portfolio recorded $83 million in revenue in Q2 declining 9% operationally.
Growth in our international diagnostics portfolio was more than offset by a decline in our U S business in the quarter.
In the U S. We experienced a decrease in sales, resulting from our new go to market model and the build out of our sizable and new dedicated field force for diagnostics.
While disruptive in the short term this.
This investment is putting the necessary fundamental elements in place to position and grow our diagnostics portfolio over the long run.
We expect the effectiveness of our new diagnostic tool for us to improve gradually over the remainder of the year.
Diagnostics remains core to our business and a key long term growth driver for <unk>.
Sales of livestock products declined 1% operationally in the quarter.
Negatively impacting growth across the portfolio, where global generic competition for Jackson and the war in Ukraine.
China swine products again declined due to lower corn prices and COVID-19 related lockdowns.
Our U S. Poultry portfolio also continues to be challenged by generics and cheaper alternatives to assortments.
Meanwhile, our fish portfolio again grew double digits in the quarter and along with the strength of our sheet products in Australia, partially offset the broader deep long.
Overall <unk> performance in the quarter continues to be in line with our expectations.
Now moving until revenue growth by segment for the quarter.
U S revenue was $1 $1 billion in the quarter growing 9% with companion animal products growing 13% and livestock sales declining 7%.
Focusing first on companion animal.
USS practice revenue trends continued to be positive with practice revenue growing approximately 5%.
Spending per visit remained strong again this quarter increasing over 7%.
Visits declined more than 2%, primarily due to a challenging prior year comparisons.
In terms of vessel traffic it is worth noting that business in the second quarter were above the number of visits pre COVID-19 in the second quarter of 2019 and the trend line for growth in visits over the last several years continued to slow favorably.
I would also like to point out that our companion animal portfolio in the U S had volume growth of 8% in the quarter.
Our injectable portfolio of products that must be administered in the vet clinic also saw volume growth in the quarter.
These products include <unk> vaccines and cohort.
Underlying demand for veterinary care remains robust throughout the country, even as people return to work while.
While labor challenges doing this as they do across most industries. We believe that <unk> revenue will continue to grow at levels above what we were seeing prior to COVID-19 as a standard of veterinary care continues to increase through innovation better they're more graphics higher compliance and more pets.
Companion animal growth of 13% in the U S was driven largely by sales once the Paraguay trio as well as key dermatology products.
Will those comparative <unk> was again strong in the quarter with sales of $208 million in the U S growing 74%.
We are pleased to see that a significant number of <unk> customers are new to the fleet tick and heartworm category altogether.
In addition, we continue to meet our clinic penetration targets and take share within individual clinics.
Is that Amex will provide additional runway for future expansion of both the broader market and revenue growth for trio.
Key dermatology products sales were $219 million for the quarter growing 11% with Abbott coincide a point each significantly contributing to growth year to date, our derm portfolio grew 16%.
Our investments to support our derm portfolio have been instrumental in driving more patients into the clinics and we will continue to invest meaningfully in this space as a large portion of those with dermatitis remain undertreated, representing an opportunity to further expand the market.
U S livestock declined 7% in the quarter, driven primarily by sales of cattle products as a result of generic competition for Jackson.
Meanwhile, our poultry portfolio continues to be negatively impacted by the expanded use of lower cost alternatives and generic competition for <unk>.
Swine product sales grew in the quarter as a result of increased this is prevalent and favorable market conditions for producers.
Moving onto our international segment, where revenue grew 2% on a reported basis and 8% operationally in the quarter.
And animal revenue grew 16% operationally and lastly revenue grew 2% operational.
Increased sales of companion animal products resulted from growth of monoclonal bodies will aviation illustrious rod is paying off.
Key dermatology products and the <unk> franchise.
These core brands continue to benefit from our international direct to consumer promotional campaigns and we remain excited with the long term prospects of these programs.
We continue to be pleased with the performance of our monoclonal antibodies for OA pain with labella generating $26 million.
So Lindsay you delivering $5 million in second quarter sales.
<unk> remains on track to exceed $100 million in revenue this year.
As we have mentioned in prior quarters. The boiler is the number one pain product in the EU with the underlying performance metrics being very favorable for Fisher growth.
Reordering rates remained high compliance continues to exceed our initial expectations and we continue to see significant opportunity to expand the pain market with meaningful percentage of thoughts on labella being new to the market.
It is also worth noting that we are observing similar pet owner investment trends in many of our key international markets that we are seeing in the U S.
The higher standard of care and better demographics as well as a more rapid adoption of innovation continuing to expand markets for our products and we expect these trends to continue.
Volume growth in our international companion animal portfolio was 10% in the second quarter and.
And we also saw growth across our injectable products, including monoclonal antibodies vaccines entitled point.
Meanwhile, International livestock grew 2% operationally in the quarter with solid growth across fish cattle and sheep.
Our fish portfolio experienced increased demand for vaccines in key salmon markets, including Chile in Norway.
Cattle grew to favorable market conditions and price in key emerging markets, including Australia, Turkey, China and the U K.
Sales of <unk> products grew as a result of favorable market conditions and new product launches in Australia.
Growth was partially offset by continued weakness with the price of pork and COVID-19 related supply challenges in China as well as unfavorable producer rotational programs with Msas in Europe, and reduced stock sizes in Latin America impacting poultry.
Now moving on to the rest of the P&L for the quarter.
Adjusted gross margins of 69, 8% decreased 120 basis points on a comparable basis to the prior year, resulting primarily from unfavorable foreign exchange effects as well as higher manufacturing freight and other costs, partially offset by favorable price and mix.
Adjusted operating expense increased 10% operationally with SG&A growth of 8% operationally driven by promotional and marketing expenses related to key brands and new product launches as well as T N equals beginning to return to pre COVID-19 levels.
R&D expenses increased 16% operationally due to higher compensation costs increased spending on projects and higher operating costs.
The adjusted effective tax rate for the quarter was 27% an increase of 70 basis points driven by changes in jurisdictional mix of earnings and lower discrete tax benefits related to share based payments.
And finally, adjusted net income grew 9% operationally and adjusted diluted EPS grew 10% operationally for the quarter.
Capital expenditures in the second quarter were $146 million.
We are still anticipating a significant increase in capital expenditures for the back half of 2022, primarily related to investments in Ireland, the U S and China to support manufacturing capacity needed to meet our long term growth demands.
In the quarter, we returned over $600 million to shareholders through a combination of share repurchases and dividends.
We repurchased approximately $450 million of Novartis shares representing our largest share repurchase ever.
Now moving on to our updated guidance for the full year of 2022.
So operational revenue growth, we are maintaining the midpoint and narrowing the range of growth to nine 5% to 10, 5% previously a 9% to 11%.
We are interesting operational growth expectations for adjusted net income to a range of 11% to 13% previously 10% to 13%.
This change in guidance signals increased confidence in the back half of the year due to the continuing outperformance of companion animal easing of certain supply constraints and an improvement in our business in China.
Please note that our guidance for adjusted interest expense and OID was changed to reflect favorable changes to interest income.
Foreign exchange rates on our updated guidance are as of late July and reflect the continued strengthening of the U S. Dollar.
Beginning with revenue for the full year 2022.
The narrowing of our range and the impact of foreign exchange. We are now projecting revenue of between eight five and $8 $3 5 billion.
We now expect adjusted net income to be in the range of $2 35 to $2 39 billion.
And finally, we expect adjusted diluted EPS to be in the range of $4 97 to.
To $5 five <unk>.
<unk> reported diluted EPS to be in the range of $4 65 to.
Two $4 75.
While our guidance represents our outlook for the full year due to the unique factors impacting our business in 2022, I would like to note that our guidance for growth, especially for revenue and adjusted net income will be weighted towards the end of the year.
While we expect operating expenses to be incurred at a similar rate across the back half of the year, we are noting an easier opex comp in Q4 than Q3 due to heavy spending in the fourth quarter last year.
Also in Q3 of last year, we experienced an unusually low adjusted effective tax rate of 16, 7% due to favorability related to foreign derived intangible income and certain discrete items, we do not expect similar favorability this year.
Our full year 2022 guidance once again reflects our value proposition of growing revenue in line with or faster than the market and growing adjusted net income faster than revenue over the long term.
Our success will continue to come from our diversified portfolio of enduring brands driven by multiple sources of inline growth.
Productive inhibition and an infrastructure to develop and expand markets globally.
We expect to continue to execute across multiple dimensions of our business and capitalize on favorable end market dynamics for the foreseeable future.
Now I'll hand things over to the operator to open the line for your questions operator.
At this time, if you would like to ask a question. Please press star one on your telephone keypad to withdraw yourself from the queue you May press the pound key.
We will take our first question from Michael Riskin of Bank of America.
Alright, Thanks for taking the question I'm going to try to squeeze in two real quick first on your comments on material competition.
Kristen certainly something thats been talked about and anticipated for a while but I'm curious if you have any updated thoughts on how youll respond it's going to be changed how you price supercuts trio or any additional promotional or did you see clients you can try implemented next six months.
I'm wondering if it's too early to give us maybe a ballpark dollar target for next year is crazy.
$1 billion in trio sales in 2023.
And then a quick follow up if I can on margins for the year.
What I'm, hoping you could can you walk us.
Back to margins, both on gross margin and Opex.
Just wondering how that factors into the updated outlook.
Sure I'll take the first one Mike Thanks for the question for starters, we were really pleased.
With the performance of <unk> trio and compare to franchise in the quarter with 72% growth and we do expect even with competition to grow the franchise here, what we're really seeing in the market as a strong shift from topicals and collars to world.
The new standard of care, so we see the category.
Certainly growing we still believe we've got a number of advantages for being first to market. We've gotten a lot of customers enrolled in auto ship, which is really helping I continue to drive growth there.
We've got strong relationships with the large corporate but importantly on that issue. We still believe we've got significant room to expand.
Penetrated clinics as we look at what our penetration within those clinics is the other thing is we really don't believe youre going to see tons of switching without significant differentiation, which honestly, we're not really expecting that remains a significant market and right now thats in Paragon franchises number two in the U S.
We tick and heartworm. So we are expecting approval of our potential competitors. Some time in the back half of this year.
And then obviously launching likely sometime next year, but we continue to believe that we can grow the franchise, we're going to invest highly in that through direct to consumer through our field force and we believe given all the issues and opportunities. We have we can continue to grow this franchise.
Yes.
Mike a question on margins and Opex.
If you look at our gross margins on a year to date basis. If you take out the impact of FX, we're running about 20 basis points above last year. So in the quarter you saw gross margins down about 120 basis points, but it's all <unk>.
<unk> driven we've effectively maintained our opex.
Growth range in our guidance and we were able to raise the bottomline guidance to 11% to 13% versus 10% to 13% that we started the year with FX.
FX is having an impact here, although we are executing according to our plan.
We'll see an improvement even on the bottom line growth rate.
Our next question comes from Erin Wright of Morgan Stanley .
Great. Thanks.
Could we get an update on <unk>.
U S approval and the supply chain constraints for that product in international market update.
At this point do you think you have visibility to supply chain constraints will have any kind of impact on the U S launch in terms of timing. After you do get approval in the U S will you be ready to broadly launch that product.
Immediately and then just in terms of the guidance how should we be thinking about what's embedded in the guidance for companion animal and livestock growth for the balance of the year are there any sort of dynamics from a quarter to quarter basis that we should be thinking about thanks.
Great. Thanks, Erinn I'll take the first one let me take that second question. We are really pleased so far in the labriola success.
Outside of the U S and we will talk a little bit what I think the implications. There. Therefore are within the U S. Right now labella is the number one OA pain product in dogs in the EU already which we think is outstanding if you look at it success, it's really been embraced and we see very strong reorder rates right now.
Impressively, 40% of dogs are new to the category and receipt of 90% reorder rate. So we're really pleased this is a product as you've noted added does share some components with human Covid vaccines, and we've been managing that very carefully making sure as we launch that we have adequate supply since this is a chronic medication.
It really has been thoughtful about that we do believe we've got additional capacity coming online and some of our suppliers as we look into the second half of this year and into next year or so.
Look at the rest of this year, we as we said we believe this product will be a blockbuster this year.
Over $100 million I'm, we're very optimistic.
Domestic assuming we get the approval as we're expecting in an inspection this year to be able to move exactly as we did in <unk> next year with an early experience in the first half followed by a full launch so remain very excited investing heavily behind that and believe we're working really hard on the supply chain unless something changes dramatically we are caught.
We will have the supply we need for a successful launch in the U S next year.
Erinn with respect to our guidance and how you should be thinking about companion animal versus livestock, so far year to date.
Delivered 9% operational growth at the topline largely driven by companion animal I think you can expect that to continue in the back half of the year when you consider.
As Christian just mentioned Celesio will be.
Fully launched in the second half in the U S.
Sure we will continue to see growth in trio and with Labella, which we expect to BSA has blockbuster in the EU. This year, we delivered $21 million in the first quarter 26 million in the second quarter. So that will continue to ramp. So I think those will contribute towards companion animal continuing to drive when I think about livestock, we do see easier comps in the back half then.
If we would've had in the first half to recall swine in China. For example prices started to really decline in the second half of last year. So that becomes an easier comp. When you think about Q3, and Q4, and therefore cattle and we did have some price adjustments in the fourth quarter last year on Jackson, leading into the started the year. So those makes it makes for a slightly easier comp from a capital.
Perspective in the fourth quarter. So so those are sort of the considerations, but I would expect the second half to look.
More like the first half in terms of the contribution from container companion they'll go to lifestyle.
Our next question is from Jon block of Stifel.
Great guys. Thanks, good morning.
Ill try to ask two losses upfront key derm I think it was up 22% operationally.
<unk>, but I think it slipped from 27% of <unk>.
To 16% in Q2, and I got a sort of a similar year ago comp. So can you talk to Christian and your thoughts on the atopic derm growth call. It just a trajectory going forward.
The chewable version offer a price premium for you guys.
And I think Christian you also talked about just no competition for.
Maybe the next 10 months just how you have that line of sight and then shifting gears second question to livestock.
That market, just always seems to be evolving would love to get your thoughts on normalized growth returning to the industry in 2023, Christopher I think you called it out last quarter does that stay intact with your growth be representative of market since I think youre going to get soon on the back end of some of the generic headwinds that you've been.
Patients thanks, guys.
Sure. Thanks, so much John I will take the first question, let me take the second one on livestock.
We are very pleased with continued growth.
To your point in the first six months of the year. It grew 22% in the quarter was 16, there always has been some cyclicality, but we really believe we can continue to grow. This franchise, we can expand it and we have been through both branded and unbranded DTC. As you know we just began this year are really an investment in.
Unbranded DTC in Europe , where we're now seeing significant pick up there.
Continue to see people home with Petsmart and importantly, they are still in the U S alone 6 million.
Who are still itching, who do not get notwithstanding the products. So we think we can continue to grow that to.
To your question on competition and lifecycle innovation, we are investing heavily behind lifecycle innovation. This is our category.
As you saw last year. The franchise is already worth $1 billion. So we will work heavily to defendants, both with chewable and with other products in the pipeline.
Google is a real advantage for a lot of people, who have trouble getting pills to their dogs and getting them to take it.
I would tell you there may be a slight price depending a very market specific as you look at the pricing there but to us it's really building the loyalty to our franchise overall, we don't have on a competition as you know it's not a perfect science in our industry.
But as you saw we did on the comparator trio, hence we do see competition, mostly that it through working with chatter in the in the marketplace as well as with our distributors and our large corporate who start negotiating differently with us when they believe theres going to be competition in our space. So we are not seeing that in the same way that we are just starting to see that now.
On the competition for our <unk> franchise. So we continue to believe we can grow this franchise with new innovation with the strength of our commercial infrastructure with our investment in DTC. So I'll, let I'll, let me take the second question on livestock, Yes. When you look at lifestyle historically, we've seen lifestyle growth around 4%.
<unk> certainly you're very familiar with what's happened the last few years in terms of ASF and for us with generic competition with Jackson and so a mix of the years essentially executing as we as we expected on livestock. We continue to believe that we can see lifestyle returning to normalized growth.
In the 2023, slash 2024 timeframe and long term, we look at life stock we continued to see.
Growth in this in this business long term given population growth.
We see urbanization as well as growing middle class, particularly as you look across emerging markets and even this year. If you look at this quarter. For example lifestyle grew 2% internationally. Despite the headwinds in swine as I said those comps get easier in the back half and as Youll get Russia, Ukraine. For example, another point there. So so we're seeing growth in emerging.
<unk> on lifecycle, we expect those to continue long term with innovation as well.
As we continue our swine vaccines that we're launching vector vaccines on the poultry side Immunotherapies.
Hello, et cetera, we would expect to continue to drive growth in livestock long term.
Our next question comes from Kristine rains of William Blair.
Hi, yes. Thanks for the question just piggybacking off of that last point can you further review those pipeline highlights millwork your livestock portfolio.
It's related on the <unk>.
Comparatively well.
Slower growth in livestock. This quarter can you discuss the factors there that drive the performance.
Performance between international and domestic here. Thanks.
Yes, sure I'd be happy to do that look I think as we entered the year, we expected given a second year of generic competition for Jackson, our largest products in cattle.
To some extent in swine as well, we expected that to drag our livestock performance in the U S and again, that's essentially is executing as we thought what that is masking somewhat is the innovation that we are launching in swine.
For example, with vaccines and swine or vector vaccines that we have been launching we'll continue.
To drive.
In livestock as well, but we are seeing growth in emerging markets you sell.
2% growth in the quarter.
But again that was offset.
Partially.
With Russia, and Ukraine impacted.
Here given the conflict.
There as well as wine as we as you know from the second half of last year, we've seen a decrease in price does impact the performance there. Although we have seen a lift in pricing on slide over the last number of weeks or months in China. We expect that to continue as we as we execute through the second half of the year.
A little bit more on your question on the pipeline and livestock to build on with what anything we do continue to believe that we're that there are significant growth opportunities in vaccines and livestock. That's what our customers are looking for as what may referenced we've been launching some vaccines and swine certainly vector vaccines, we just announced at approval the second vector vaccine and <unk>.
<unk> will be launching more vector vaccines in that poultry franchise as well really excited as I mentioned earlier about fish with 23% broke in the quarter Apple flex really focusing on sea lice at other potential vaccines. There and then you look at that more broadly as we look at it a little harder investment of Immunotherapies as.
As well as in precision livestock farming.
Anything to add to our block aerie product there two of our genetics business. There. So we do see a number of key platforms in livestock to drive innovation in this space.
Said I think you can get back to the historical growth rates of around 4% as we.
Hopefully lap some of this generic.
Issues around Jackson.
Mix in poultry in the ASF issue.
In China, but I think to get above that which we certainly aspire to deal it's going to take bringing innovation and we are certainly investing to be the leader in innovation in livestock.
Our next question comes from Nathan Rich of Goldman Sachs.
Hi, good morning, Thanks for the question Jim.
You talked about the capacity and labor constraints that clinics are facing but.
I think you noted vaccines and injectable products continued to grow I guess can you maybe talk to your ability to continue to grow those products in the current market backdrop and I guess ultimately the bigger picture question is if we see these market dynamics, both from a macro standpoint as well as.
Some of the pressures of the clinics are facing continue into next year I guess.
How should we think about growth I guess should we expect a similar level of companion animal growth as to what you're guiding to in the back half. Thank you.
Sure.
What's important to keep in mind is that that clinics are doing quite well. If you look at growth in vet clinic revenue since 2019, it's up 20%.
There is definitely with a 5% increase in the number of pets in the U S. There are capacity constraints to meeting all the needs, but I think what's important to remember also is we are not leveraged as highly as some other businesses to in clinic visits.
What are our key products are chronic so if you look at our current portfolio, our Paris portfolio et cetera.
Still seeing.
Tremendous growth, we had a 10% volume increase in the quarter in U S product.
Product. So I think it's important to think there is more moving to online and other spaces. So we don't see some of this capacity issues as a major issue for us in continuing to grow our business.
We're seeing some of the same capacity strength in Europe , and yet youre already seeing us have labella.
Looking to be a blockbuster product this year and I think what really differentiate us is innovation, whether it's important science and new products that we're excited about we're still seeing great attention at the vet clinic for that and really driving that through although a lot of people are very focused on that because it's given we're not as leveraged to that.
<unk>.
We really think the spend per visit is really important and I think we are leading in that category given innovation.
Our next question comes from Louise Chen of Cantor Fitzgerald.
Alright, Thank you for taking my question here.
Ask you are there any metrics that you can point to to support pricing and demand elasticity in the pet health space and then do you think about this the same way and livestock. Thank you.
Well I think certainly when we when we look at price and demand we've continued to see opportunities to take price at or above inflation and we've demonstrated that.
Over the years, particularly in certain markets. We've also looked at data in terms of pet ownership and demographically, we see.
The structural.
Improvements I would say even compared to very strong basis to begin with so if you look at pet ownership with respect to Gen Z and millennials.
And they are prioritizing pet health, that's certainly bodes well, but also we're seeing more adoption at higher income households.
What adoption numbers look like over the last number of years, which again is structurally very positive.
The industry, so as we've taken price over the years and we took about 5% price.
In companion animal this year overall for the company, it's been running about 3% net given some of the lifestyle dynamics that particular Jackson.
Competition.
But we have we haven't been able to take price and yet we still continue to see strong volume growth across the business and to Christians point, largely driven as well by innovation in this space. So we continue to see the elasticity in terms of ability to take price.
At or above what we see from an inflationary perspective.
Okay.
Our next question comes from Elliot Wilbur of Raymond James.
Thanks, Good morning.
Just a follow up question for Christian around Parasiticide trends in the quarter can you maybe just talk about category growth overall, it seemed like some of the metrics out there suggested that.
Overall category growth had actually been down and obviously trio continues to perform extraordinarily well, particularly in the U S and I'm just thinking about.
The second half of the year and then early next year with a potential entrant what youre seeing in terms of category growth and if you could just give us the number in terms of where <unk> is with respect to.
Overall share in the category if I can just get a quick follow up in here on <unk>.
Obviously, the initial EU experience has been quite positive here I think you mentioned that 40% of.
Pets were new to therapy, just wanted to get maybe an update in terms of what youre seeing with respect to persistence. Some of the pets that started therapy initially.
And sort of where we were.
What kind of persistence rates youre seeing in sort of six to seven months. After beginning therapy and is that 40% is that sort of a normal level in terms of new pets coming into the market or should the takeaway there be that library, that's where that has really kind of elevated the overall category growth.
Thanks.
Thanks, Elliot I'll start with your Labella LLC maybe.
Maybe he can add anything on that at the Paris point.
Really good questions. There on labella, if you look at the 40% new to the category. We do think Thats extraordinary. This is an established category. This isn't like German we started it where it wasn't really a category there have been many products across the globe for dogs for pain management, but I think it really underscores the challenges with the existing therapy.
The tradeoffs on safety and efficacy had been significant most of those therapies you can't stay on for a very long and I think so for a lot of people that.
Really didn't want to deal with some of the side effects that they had stayed out of the category I think was something with the label that we have with a monoclonal antibody. We are clearly, bringing new people to the sector and we're growing that sector significantly I think we talked about before the global market for pain for dogs with around $400 million, we built.
<unk> with the addition of labella that we can double the size of that market over time and move that to 800, and we think we can do that from a few ways and one of them you referenced one is people staying on therapy longer.
Certainly with a safe and efficacious product. We believe we can increase days on therapy. I think we can also we demonstrate with a 40% increase the number of pets getting it and third we think we can grow the market certainly based on price. So this is a premium product with significant innovation. So we're really pleased with the 40% growth. It is certainly higher than even we were expect.
With the new patients to the category, we are seeing significant.
Probably higher than we were expecting initially.
Compliance in the sense of months on therapy.
Remain extremely optimistic about EU am I on the persistence of this growth and I'll. Let me take your follow up question on Paragon, Yes, when we look at the category broadly speaking clearly trio grew 72% in the quarter. If you look at our overall.
<unk> franchise grew 47% rate, so if Yogurts America, not trio, but super Erica internationally.
93% in the quarter. So we have the broadest offering and towards a parasiticide in the industry and clearly the only triple combination in the U S. But we are seeing is categorically, we're seeing a shift from topical and colors to all medications and it feels good triple combination in the U S. One.
One of the interesting stuff.
Statistics that we've seen is that Ontario about 30% of the dogs that are coming in Ontario are new to the category and that hasnt been prescribed.
A prescription the upper set aside in the prior 18 months or so so we do see significant room to continue to expand in this space and as competitors come into the space there'll be more DTC that will drive even more patients to the clinic, which is beneficial for us as well given our relationships across our corporate accounts and so on will benefit from having more voice.
As our driving more patients into the clinic. So we're not seeing a slowdown in the category. There is a bit of a shift from the topical and callers intervals and that benefits us given our premium products.
Our next question comes from <unk> Prasad of Barclays.
Hi, good morning.
Originations results two for me Firstly, I just talked to lap the impact of generates on Blackstone's Zomax would just till 'twenty generalization.
Generalization as a top two or top three challenge over the next two years and you can also add some broader comments on the present agency portfolio exposed to generic competition I'll just spend also on diagnostics.
Operational decline of 9% it seems to be the first quarter of decline after Q2 2020.
And in contrast European results. So wondering what kind of increased public <unk> noticed that you've been calling out over the past few months and any metrics that again.
Between point, a scan or reference labs.
It helps us understand this performance. Thank you.
Sure I'll start with your diagnostics and iron ore.
Getting sort of deal with that drop in lifestyle question. As you look at we're about flat in the first half of the year in diagnostics and as <unk> mentioned in his remarks.
As you saw the decline really there was growth in international we made a huge investment in creating a standalone diagnostics field force and technical team and service team in the U S that is highly disruptive as you know if you watched other companies do this over time.
So, but we do believe in the absolute strength of this business long term investing in it long term as you've seen we've invested in innovation and our imaging platform etcetera to grow this business. So.
Obviously as that people get into new territories et cetera, There's obviously some disruption that happens there.
Honestly it was anticipated.
Remain extremely optimistic in the growth of this business and the strength of it is we certainly look at the strength of our international business and how well that's been doing and growing that with customers. We're invested in diagnostics for the long term and really believe we can drive strong growth here and diagnostics as the sector grows faster than the overall animal health space and we believe we can bring disruptive.
<unk> innovation to the space to help us drive that but I'll, let let me take the follow up question on livestock contraction, yes, sure. If you look at your accident rate that was the largest product that we have across our livestock portfolio.
There isn't any other product, that's even nearly that that size and magnitude as you look across our portfolio clearly as well in companion animals during more products that are anywhere near any sort of.
So we would not anticipate after the first two years that the generic competition element will be the key driver here in the business as we said, we expect livestock to be returning back to sort of normalized growth in the 'twenty three 'twenty four time frame.
<unk> is what we would expect and that will go towards generics Stephane.
Okay.
Our next question is from Chris Schott of Jpmorgan.
This is a catarina on from Chris from Jpmorgan. Thank you so much for taking our questions.
My question is on the macroeconomic environment you're right.
Any notable differences when it comes to popular demand across geographies. So Europe appears to be getting hit harder by some of the challenges we need to fuel cost Q.
Quick question, just a quick one I was wondering if youre starting to see any changes.
Here in that market.
Thank you sure Thanks cut arena.
How do you on the call today and you look at the sort of macroeconomics, we continue to see on a global basis very strong demand and I think what's driving that for US is the innovation that we bring to the market as well as who's adopting some of these dogs.
Lineal Gen Z, who are more willing to spend more on their path as well as more of the pets being adopted by high income families. You know that being said Catarina as you double click.
Into individual markets, you are seeing as economies get affected.
Honestly overall.
<unk> may go down, but not we have so far not seen it in our products. We are monitoring it carefully I think the one place where we're starting to see a little bit more of that might be Latin America, just given some of the really hyper inflationary markets that youre starting to see there, but what we've really been pleased about in companion animal is the continued strength and willingness to spend and investing.
And innovation disruptive technology. So there are certainly differences as you get into individual markets across the globe, but overall continued strong demand and I would double quick for you.
Since you asked the global question in a few places.
In Brazil, where we only printed about 1% growth.
In Q2 overall companion animals still grew 35% in the quarter and you look at China, where we only had 3% growth companion animal grew 24%. So even in what many people might consider emerging markets. We are still seeing incredibly strong demand for our products and for our innovation.
And this does conclude our question and answer session for today I'd be happy to return the call to our host for any concluding remarks.
Great well. Thank you everyone for your questions and for your continued interest in that way. That's just to summarize we see continued strength across our diverse global portfolio, especially in our companion animal and pet care products, we are continuing to invest in talent and innovation and manufacturing expansion that can support our future growth.
<unk>.
And we are updating and narrowing our full year guidance to reflect a positive outlook for the remainder of 2022 and obviously as many other companies the negative impact of recent changes to foreign exchange rates. So I look forward to keeping updated on future calls. So thanks, so much have a great day.
This does conclude the <unk> Q2, 2022 earnings Conference you May now disconnect your lines and everyone have a great day.